Posts Archive

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell...

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple...

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...

NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis NCT04754945: Phase 1: Isatuximab as...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...

Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...

NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or...

MagnetisMM-3 NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma Relapsed & Refractory...

NCT04352205: Phase 2: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205:...

NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple...

NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma Personalized Autologous Transplant for Multiple Myeloma...

KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...

CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...

NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma Low-Dose Radiotherapy in...

NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255 in Relapsed/Refractory Multiple...